Table 3.
Inflammation markers after 4 weeks placebo and agraz consumption.
| Variables | Placebo | Agraz | Δ Change (Agraz-Placebo) Mean ± SD | p | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n | Mean ± SD | n | Mean ± SD | |||||||||
| IL-1β (pg/mL) | 37 | 0.8 | ± | 0.4 | 37 | 0.8 | ± | 0.4 | 0.0 | ± | 0.2 | 0.748 |
| IL-6 (pg/mL) | 37 | 2.6 | ± | 2.1 | 37 | 2.1 | ± | 1.2 | −0.5 | ± | 1.5 | 0.271 |
| IL-8 (pg/mL) | 37 | 12.6 | ± | 5.6 | 37 | 12.1 | ± | 5.5 | −0.3 | ± | 2.6 | 0.322 |
| MCP-1 (pg/mL) | 38 | 251 | ± | 103 | 38 | 248.3 | ± | 106.6 | −2.6 | ± | 47.3 | 0.479 |
| TNF-α (pg/mL) | 38 | 4.7 | ± | 1.8 | 38 | 4.6 | ± | 1.5 | −0.1 | ± | 0.8 | 0.257 |
| NF-κB (abs) | 38 | 0.1 | ± | 0.02 | 38 | 0.1 | ± | 0.02 | 0.0 | ± | 0.02 | 0.290 |
SD, standard deviation; TNF-α, tumor necrosis factor-alpha; IL, interleukin; MCP-1, monocyte chemoattractant protein-1; NF-κB, nuclear factor kappa B. Paired t-test was used for the analysis. Significance p < 0.05.